Article
Public, Environmental & Occupational Health
Rachel L. Ross, Karl Rubio, Hector P. Rodriguez
Summary: This study examines the association between physician practice decision-aid use and mammography rates among older women. The results showed that advanced health information technology functions were associated with mammography use, while practice use of decision aids was not. Beneficiary characteristics had a stronger association with mammography use than practice-level decision-aid use or advanced health information technology functions.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2022)
Article
Oncology
Jean-Luc Bulliard, Anna-Belle Beau, Sisse Njor, Wendy Yi-Ying Wu, Pietro Procopio, Carolyn Nickson, Elsebeth Lynge
Summary: The study focused on quantifying the variation in estimated breast cancer overdiagnosis in organised programmes, using observed and simulated data, as well as modelling to provide additional insights. Reliable observational data and modeling studies suggest that less than 10% of invasive breast cancer cases in a screening population of women aged 50 to 69 are due to overdiagnosis. Results suggest that estimates above this level may be attributed to inaccuracies in study design, directing the need for improved methodology in future research.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
David F. Yankelevitz, Claudia I. Henschke
Summary: There has been ongoing concern and confusion about overdiagnosis in lung cancer screening, with the current definition and frequency of occurrence remaining unclear. The lack of clarity stems from the current epidemiologic definition, which does not consider the clinical presentation of cancer, leading to confusion about the actual rate of overdiagnosis.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Sandra Gonzalez Maldonado, Erna Motsch, Anke Trotter, Hans-Ulrich Kauczor, Claus-Peter Heussel, Silke Hermann, Sylke Ruth Zeissig, Stefan Delorme, Rudolf Kaaks
Summary: A study on lung cancer screening among long-term smokers revealed a risk of overdiagnosis in the screening group, especially for individuals with shorter life expectancies. The excess cumulative incidence in the screening arm was largely driven by adenocarcinomas, suggesting a major risk of overdiagnosis for individuals with comparatively short remaining life expectancies.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Andrew J. Vickers, Amit Sud, Jonine Bernstein, Richard Houlston
Summary: The study proposes using polygenic risk scores (PRSs) based on single-nucleotide polymorphisms (SNPs) to determine high-risk subgroups for cancer screening. However, these PRSs only predict cancer incidence and do not address the issue of overdiagnosis. The authors develop a net-benefit framework to evaluate screening strategies, and find that screening based on a marker that predicts cancer mortality rather than incidence can lead to greater net benefits.
NPJ PRECISION ONCOLOGY
(2022)
Article
Medicine, General & Internal
Paul F. Pinsky, Howard Parnes
Summary: Screening for prostate cancer should take into consideration the risks and benefits. PSA screening can reduce prostate cancer deaths, but the reduction is small. Follow-up tests such as biopsy and MRI may be needed for individuals with elevated PSA levels. Patients with low-risk or favorable intermediate-risk prostate cancer may choose active surveillance over immediate curative treatment. Surgery and radiation therapy have good outcomes but can lead to complications.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Danielle D. Durham, Jennifer M. Croswell, Pamela M. Marcus
Summary: Overdiagnosed cancers are those that are screen-detected and would never have become symptomatic during the patients' lifetime. The National Lung Screening Trial (NLST) found that competing cause of mortality (CCM) overdiagnosis was not common, but it may be more frequent in community-based screening due to higher prevalence of comorbidities.
Editorial Material
Oncology
Jessica Chubak, Andrea N. Burnett-Hartman, William E. Barlow, Douglas A. Corley, Jennifer M. Croswell, Christine Neslund-Dudas, Anil Vachani, Michelle Silver, Jasmin A. Tiro, Aruna Kamineni
Summary: The accuracy and efficiency of cancer screening tests rely on various factors, and the length of the accuracy assessment interval can introduce bias in sensitivity and specificity estimates. Future research should aim to quantify this bias and provide guidance on setting appropriate assessment intervals for different types of cancers and screening methods.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Lilu Ding, Keris Poelhekken, Marcel J. W. Greuter, Inge Truyen, Harlinde De Schutter, Mathijs Goossens, Nehmat Houssami, Guido Van Hal, Geertruida H. de Bock
Summary: This study aimed to estimate the overdiagnosis rate of invasive breast cancer in an organised screening program, with results showing a higher overdiagnosis issue in older women and the importance of sufficient follow-up time for obtaining accurate estimates.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Mengmeng Li, Li Zhang, Hadrien Charvat, Matthew E. Callister, Peter Sasieni, Evangelia Christodoulou, Rudolf Kaaks, Mattias Johansson, Andre L. Carvalho, Salvatore Vaccarella, Hilary A. Robbins
Summary: This study aimed to understand the reasons behind the variations in estimates of overdiagnosis in low-dose computed tomography (LDCT) lung cancer screening trials. A systematic review was conducted to identify these estimates from randomized controlled trials of LDCT screening. The association between Ps (the excess incidence of lung cancer as a proportion of screen-detected cases) and postscreening follow-up time was analyzed. The results showed that differences in postscreening follow-up time could partially explain the variations in overdiagnosis estimates across trials. The findings emphasize the importance of considering postscreening follow-up and population characteristics when interpreting estimates of overdiagnosis.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry R. Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte
Summary: Prostate-specific antigen (PSA) screening for prostate cancer remains controversial due to overdiagnosis and overtreatment. However, accounting for genetic determinants of PSA variation may improve screening accuracy.
Review
Oncology
Theis Voss, Mikela Krag, Frederik Martiny, Bruno Heleno, John Brandt Brodersen, Karsten Juhl Jorgensen
Summary: The degree of overdiagnosis in common cancer screening trials is uncertain due to inadequate design and varying methods used to estimate overdiagnosis. This study aimed to quantify the risk of overdiagnosis in cancer screening programs and assess the impact of design limitations and biases in trials. Overall, there is a significant risk of overdiagnosis in these trials, and the true extent is likely underestimated.
CANCER EPIDEMIOLOGY
(2023)
Review
Health Care Sciences & Services
Arwa F. Flemban
Summary: A systematic review and meta-analysis were conducted to estimate the incidence of overdiagnosis due to screening mammography for breast cancer among women aged 40 years and older. A total of 30 articles were included in the analysis, and the incidence of overdiagnosis was found to be 12.6%. Despite heterogeneity among the articles, this study highlights the need for some level of overdiagnosis allowance in breast cancer screening and the importance of minimizing harmful consequences associated with it.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Public, Environmental & Occupational Health
Jenna Smith, Rachael H. Dodd, Jolyn Hersch, Kirsten J. McCaffery, Vasi Naganathan, Erin Cvejic, Jesse Jansen
Summary: The study found that some older adults continue cancer screening despite guidelines suggesting they should not, and psychosocial factors may be the main driver for their decision. Reasons for screening intention include routine adherence, recognizing the value, positive attitudes, and more.
PATIENT EDUCATION AND COUNSELING
(2021)
Article
Oncology
Anna N. Wilkinson, Larry F. Ellison, Jean-Michel Billette, Jean M. Seely
Summary: The study found that screening programs including women in their 40s were associated with a significantly higher 10-year breast cancer survival rate for women aged 40-49, without increasing the diagnosis rate of breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)